Overview Dividends

(SEM) Select Medical Holdings - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US81619Q1058

Hospitals, Rehabilitation, Outpatient Clinics, Therapy Services

Health Care Facilities
Market Cap in USD: 1,737m

IPO / Inception: 2009-09-25
Return 12m vs S&P 500: -33.5%

EPS (Earnings per Share)

EPS CAGR: -11.91%
EPS Trend: 5.6%

Last SUE: 0.54
Qual. Beats: 0

Revenue

Rev. CAGR: -3.52%
Rev. Trend: -26.6%

Last SUE: 0.06
Qual. Beats: 0

Dividends

Dividend Yield	1.62%
Yield on Cost 5y	2.06%
Yield CAGR 5y	10.06%
Payout Consistency	45.6%
Payout Ratio	17.4%

Risk via 10d forecast
Volatility	41.2%
Value at Risk 5%th	61.4%
Relative Tail Risk	-9.34%

Reward TTM
Sharpe Ratio	-0.54
Alpha	-37.41
CAGR/Max DD	0.17

Character TTM
Hurst Exponent	0.451
Beta	0.779
Beta Downside	0.801

Drawdowns 3y
Max DD	45.06%
Mean DD	16.16%
Median DD	14.07%

Description: SEM Select Medical Holdings November 13, 2025

Select Medical Holdings Corp. (NYSE: SEM) operates a network of critical-illness recovery hospitals, rehabilitation hospitals, and outpatient rehab clinics across the United States, organized into three reporting segments.

The Critical Illness Recovery segment treats patients with heart failure, respiratory failure, renal disease, neurological events, trauma and post-surgical recovery, while the Rehabilitation Hospital segment focuses on brain and spinal cord injuries, strokes, orthopedic and pediatric conditions, and cancer-related rehab. The Outpatient Rehabilitation segment delivers physical, occupational and speech therapy plus specialty programs such as hand therapy, pelvic health, and post-concussion care.

In FY 2023 the company reported $2.1 billion in revenue, a 7 % YoY increase driven largely by outpatient volume growth (≈ 12 % YoY) and higher case-mix intensity in the critical-illness segment. Adjusted EBITDA margin expanded to 9.3 % from 8.1 % a year earlier, reflecting improved cost-control and better payer reimbursement rates.

Key macro drivers include the U.S. aging demographic (the 65-plus population is projected to reach 22 % by 2035), ongoing Medicare policy shifts that favor bundled payments for post-acute care, and a broader industry trend toward outpatient rehabilitation services, which typically offer higher margin potential than inpatient stays.

For a deeper, data-rich analysis of SEM’s valuation and risk profile, you may find ValueRay’s research platform worth a quick look.

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (110.0m TTM) > 0 and > 6% of Revenue (6% = 236.0m TTM)

FCFTA 0.03 (>2.0%) and ΔFCFTA -1.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 2.06% (prev 2.62%; Δ -0.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 407.6m > Net Income 110.0m (YES >=105%, WARN >=100%)

Net Debt (971.5m) to EBITDA (232.7m) ratio: 4.17 <= 3.0 (WARN <= 3.5)

Current Ratio 1.09 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (123.5m) change vs 12m ago -0.97% (target <= -2.0% for YES)

Gross Margin 8.24% (prev 13.22%; Δ -4.99pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 57.47% (prev 75.60%; Δ -18.12pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 0.80 (EBITDA TTM 232.7m / Interest Expense TTM 103.7m) >= 6 (WARN >= 3)

Altman Z'' 0.88

(A) 0.01 = (Total Current Assets 1.02b - Total Current Liabilities 939.6m) / Total Assets 5.69b

(B) 0.15 = Retained Earnings (Balance) 824.8m / Total Assets 5.69b

(D) 0.22 = Book Value of Equity 818.7m / Total Liabilities 3.67b

Total Rating: 0.88 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 44.27

1. Piotroski 2.0pt

2. FCF Yield 6.42%

3. FCF Margin 4.42%

4. Debt/Equity 0.61

5. Debt/Ebitda 4.17

6. ROIC - WACC (= -4.56)%

7. RoE 6.51%

8. Rev. Trend -26.64%

9. EPS Trend 5.57%

What is the price of SEM shares?

As of November 27, 2025, the stock is trading at USD 15.57 with a total of 3,702,789 shares traded.
Over the past week, the price has changed by +21.64%, over one month by +10.09%, over three months by +18.69% and over the past year by -24.01%.

Is SEM a buy, sell or hold?

Select Medical Holdings has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy SEM.

Strong Buy: 4
Buy: 1
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the SEM price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	18.2	16.7%
Analysts Target Price	18.2	16.7%
ValueRay Target Price	15.3	-2.1%

SEM Fundamental Data Overview November 26, 2025

Market Cap USD = 1.74b (1.74b USD * 1.0 USD.USD)
P/E Trailing = 17.0854
P/E Forward = 11.236
P/S = 0.3236
P/B = 1.0005
P/EG = 1.37
Beta = 1.06
Revenue TTM = 3.93b USD
EBIT TTM = 82.9m USD
EBITDA TTM = 232.7m USD
Long Term Debt = 1.74b USD (from longTermDebt, last quarter)
Short Term Debt = 213.0m USD (from shortTermDebt, last quarter)
Debt = 1.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 971.5m USD (from netDebt column, last quarter)
Enterprise Value = 2.71b USD (1.74b + Debt 1.03b - CCE 60.1m)
Interest Coverage Ratio = 0.80 (Ebit TTM 82.9m / Interest Expense TTM 103.7m)
FCF Yield = 6.42% (FCF TTM 174.0m / Enterprise Value 2.71b)
FCF Margin = 4.42% (FCF TTM 174.0m / Revenue TTM 3.93b)
Net Margin = 2.80% (Net Income TTM 110.0m / Revenue TTM 3.93b)
Gross Margin = 8.24% ((Revenue TTM 3.93b - Cost of Revenue TTM 3.61b) / Revenue TTM)
Gross Margin QoQ = 10.81% (prev 11.60%)
Tobins Q-Ratio = 0.48 (Enterprise Value 2.71b / Total Assets 5.69b)
Interest Expense / Debt = 2.90% (Interest Expense 29.9m / Debt 1.03b)
Taxrate = 21.01% (11.7m / 55.9m)
NOPAT = 65.5m (EBIT 82.9m * (1 - 21.01%))
Current Ratio = 1.09 (Total Current Assets 1.02b / Total Current Liabilities 939.6m)
Debt / Equity = 0.61 (Debt 1.03b / totalStockholderEquity, last quarter 1.69b)
Debt / EBITDA = 4.17 (Net Debt 971.5m / EBITDA 232.7m)
Debt / FCF = 5.58 (Net Debt 971.5m / FCF TTM 174.0m)
Total Stockholder Equity = 1.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.93% (Net Income 110.0m / Total Assets 5.69b)
RoE = 6.51% (Net Income TTM 110.0m / Total Stockholder Equity 1.69b)
RoCE = 2.41% (EBIT 82.9m / Capital Employed (Equity 1.69b + L.T.Debt 1.74b))
RoIC = 1.88% (NOPAT 65.5m / Invested Capital 3.49b)
WACC = 6.43% (E(1.74b)/V(2.77b) * Re(8.89%) + D(1.03b)/V(2.77b) * Rd(2.90%) * (1-Tc(0.21)))
Discount Rate = 8.89% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.13%
[DCF Debug] Terminal Value 78.74% ; FCFE base≈245.4m ; Y1≈302.8m ; Y5≈516.6m
Fair Price DCF = 60.52 (DCF Value 7.49b / Shares Outstanding 123.8m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 5.57 | EPS CAGR: -11.91% | SUE: 0.54 | # QB: 0
Revenue Correlation: -26.64 | Revenue CAGR: -3.52% | SUE: 0.06 | # QB: 0

Additional Sources for SEM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle